Overview: Accurate pancreatic tissue classification for the diagnosis and differentiation of pancreatic andenocarcinoma and chronic pancreatitis
Background: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is commonly used to detect early-stage pancreatic adenocarcinomas, but is hindered by poor negative predictive value (cannot accurately exclude the presence of cancer) leading to delay, further testing and possibly unnecessary surgery. Furthermore, EUS-FNA is unable to consistently distinguish pancreatic adenocarcinoma from chronic pancreatitis.
Early stage chronic pancreatitis is challenging to diagnose, as well, so there remains intrinsic value to confirming an enigmatic diagnosis in the patient with severe, unexplained abdominal pain, where pancreatic disease remains possible.
This technology employs an optical spectroscopy method to more accurately detect cancer and differentiate chronic pancreatitis from normal pancreas. It can be used to interrogate pancreatic tissues during minimally invasive endoscopic procedures or surgery, is portable, rapid, and does not require the administration of exogenous contrast agents to patients.
Applications ¥ Handheld surgical probe or needle-based endoscopic probe to detect chronic pancreatitis and pancreatic adenocarcinoma ¥ Platform for other EUS-FNA diagnostic applications ¥ Platform for tumor margin detection in the pancreas
Advantages ¥ Improved sensitivity and specificity to detect chronic pancreatitis and pancreatic adenocarcinoma ¥ Rapid, real-time feedback; Label-free tissue diagnostics ¥ Quantitative tissue sensing / mapping ¥ Non- or minimally-invasive; Proof of concept in human tissues, in vivo ¥ Patented and patent applications filed
Patent Status: Three Issued U.S. patents (8,239,139; 8,234,078; 8,694,266). A recently filed provisional patent application (worldwide rights available) covers a miniaturized device deployable within an EUS-FNA needle.